Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Patients with advanced epithelial ovarian cancer who were non-Hispanic Black, older, had lower household income, resided in ...

To optimize treatment outcomes for patients whose late-stage cancer shows resistance to the standard treatment, Sarasota Memorial Research Institute will participate in testing an experimental ...

Investigators at the UCLA Health Jonsson Comprehensive Cancer Center have validated a test that can accurately predict which ...

Adding afuresertib to paclitaxel did not improve outcomes in patients with platinum-resistant ovarian cancer in a phase 2 trial.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

A new drug tested in a phase 3 trial showed significant improvement in patients with treatment-resistant ovarian cancer.

Ovarian cancer—known as a silent killer due to its inability to showcase most of its symptoms—kills many women every year across the world. According to studies, over a third of women are not familiar ...

Ovarian cancer is one of those. Ovarian cancer starts in the ovaries, which are two small glands located on either side of ...

After you’ve gone through ovarian cancer treatment, your doctor will work with you to make sure you stay well. But sometimes the cancer returns. Doctors call this “recurrence.” To check for ...

A common blood test may miss ovarian cancer in some racial groups Black and Native American women are more likely to get false negative results Experts say the test may need to be changed to help all ...

Friday, Oct. 24, 2014. (AP Photo/Pablo Martinez Monsivais, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] A common blood test may miss ovarian cancer in some Black and ...